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The Gerbich blood group system: a review
P.S. Walker and M.E. Reid
Antigens in the Gerbich blood group system are expressed on 
glycophorin C (GPC) and glycophorin D (GPD), which are both 
encoded by a single gene, GYPC. The GYPC gene is located on 
the long arm of chromosome 2, and Gerbich antigens are in-
herited as autosomal dominant traits. There are 11 antigens in 
the Gerbich blood group system, six of high prevalence (Ge2, 
Ge3, Ge4, GEPL [Ge10*], GEAT [Ge11*], GETI [Ge12*]) and 
five of low prevalence (Wb [Ge5], Lsa [Ge6], Ana [Ge7], Dha 
[Ge8], GEIS [Ge9]). GPC and GPD interact with protein 4.1R, 
contributing stability to the RBC membrane. Reduced lev-
els of GPC and GPD are associated with hereditary elliptocy-
tosis, and Gerbich antigens act as receptors for the malarial 
parasite Plasmodium falciparum. Anti-Ge2 and anti-Ge3 have 
caused hemolytic transfusion reactions, and anti-Ge3 has pro-
duced hemolytic disease of the fetus and newborn (HDFN).
Immunohematology 2010;26:60–65.
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History
 In 1960, Rosenfi eld et al.1 described the fi rst examples 
of anti-Gerbich in the sera of three women, including Mrs. 
Gerbich, after whom the blood group system is named. A 
year later, Cleghorn2 and Barnes and Lewis3 reported on a 
Turkish Cypriot woman, Mrs. Yus, whose RBCs were com-
patible with two of the original three sera but were incom-
patible with serum from Mrs. Gerbich. In 1970, Booth et 
al.4 reported on the prevalence of the Gerbich (GE) blood 
group in Melanesians, and in 1972, Booth5 reported that 
certain Ge+ individuals demonstrated an antibody that was 
compatible with RBCs expressing the Gerbich or the Yus 
phenotype, but was incompatible with up to 15 percent of 
Ge+ Melanesians.
 After Zelinski et al.6 demonstrated that Gerbich is ge-
netically discrete from all other existing systems, the Ger-
bich antigen collection (ISBT Collection 201) was upgraded 
to the GE blood group system (ISBT system symbol GE and 
number 020) by the ISBT Working Party on Terminology 
for Red Cell Surface Antigens.7
Biochemistry
 In 1984, Anstee et al.8 reported that individuals 
who lack Gerbich blood group antigens have alterations 
in their erythrocyte membrane sialoglycoproteins. In 
1984, these proteins were called β-syaloglycoprotein and 
γ-syaloglycoprotein; however, the current terminology is 
glycophorin C (GPC) and glycophorin D (GPD). Gerbich 
antigens are found on GPC and GPD. These sialic acid–rich 
glycoproteins are also known as CD236R, and they attach 
to the RBC membrane through an interaction with protein 
4.1R and p55. GPC and GPD contain three domains: an ex-
tracellular NH2 domain, a transmembrane domain, and an 
intracellular or cytoplasmic COOH domain (Figure 1). GPC 
and GPD are encoded by the same gene, GYPC. When the 
fi rst AUG initiation codon is used, GPC is encoded, whereas 
when the second AUG is used, GPD is encoded. Thus, GPD 
is a shorter version of GPC, and the amino acids in GPD 
are identical to those found in GPC but lacking the fi rst 21 
amino acids at the N-terminal of GPC.9,10
Review
Fig. 1. Molecules (glycophorin C [GPC] and glycophorin D [GPD]) 
showing location of various Gerbich antigens. The stick fi gures give 
the amino acid residue numbers defi ning the extracellular, transmem-
brane, and intracellular domains of GPC and GPD. Also shown is the 
trypsin cleavage site and location of all antigens except Lsa, which is 
the result of amino acids encoded by the duplication of exon 3.
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 Certain Gerbich antigens (Ge4, Wb, Dha, GEAT) are 
only expressed on GPC, two (Ge2, Ana) are only expressed 
on GPD, and others (Ge3, Lsa, GEIS, GEPL, GETI) are ex-
pressed on both GPC and GPD. Despite the fact that GPC 
possesses all of the amino acids that are found on GPD, the 
likely explanation for why some antibodies only react with 
GPD is that the antibodies require a conformational epitope 
that is present at the amino terminus of GPD but absent in 
the subterminal amino acid sequence of GPC. Some exam-
ples of anti-Ge2 do not react with RBCs after the acetylation 
of membrane proteins with acetic anhydride, suggesting 
that a free amino group is involved in the epitope detected 
by these antibodies.11 A diagram showing the trypsin cleav-
age site and location of Ge2, Ge3, and Ge4 antigens is given 
in Figure 1.
 In 1990, Reid et al.12 reported that GPC plays a function-
ally important role in maintaining erythrocyte shape and 
regulating the membrane properties through its interaction 
with protein 4.1R. In 1993, Alloisio et al.13 showed that p55, 
a peripheral membrane protein in human erythrocytes, is 
associated in precise proportions with the protein 4.1R–
GPC complex, linking the cytoskeleton and the membrane. 
The absence of GPC and GPD is associated with hereditary 
elliptocytosis, which is described later in this discussion.
Inheritance and Molecular Genetics
 In 1986, Colin et al.14 cloned the gene GYPC, and Mattei 
et al.15 determined that GYPC is located on chromosome 2, 
in the region of q14–q21. The GYPC gene consists of 13.5 
kilobase pairs (kbp) of gDNA, comprising four exons. Ex-
ons 2 and 3 are homologous, with less than 5 percent nu-
cleotide divergence. This can lead to unequal crossing over 
during meiosis and loss (outsplicing) of exon 2 or exon 3. In 
1987 Le Van Kim et al.16 reported that a deletion of approxi-
mately 3 kb in the GYPC gene is associated with the Gerbich 
blood group deficiency types Yus (GE:–2,3) and Gerbich 
(GE:–2,–3). In 1989, High et al.17 reported that the absence 
of exon 2 results in the Yus phenotype, whereas the absence 
of exon 3 results in the Gerbich phenotype. The Gerbich 
phenotype has also been produced by a nucleotide change 
and deletion of exon 3 of the GYPC.18 The Leach phenotype 
(GE:–2,–3,–4) may be produced by two different mecha-
nisms. The “PL” type of the Leach phenotype is caused by 
a deletion of exons 3 and 4, whereas the “LN” type is a con-
sequence of a 131G>T nucleotide change (134delC in exon 
3; Trp44Leu) that leads to a frame shift and a premature 
stop codon. Other Ge antigens are a consequence of nucle-
otide changes in GYPC (Table 1).19 The products of the Ge 
alleles are inherited in an autosomal codominant manner.20 
A gene map is shown in Figure 2.
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ATG
for GPC
Exon 1 Exon 2 Exon 3 Exon 4 724 bpFig. 2. Glycophorin C (GYPC) gene map. GYPC is 
composed of four exons and three introns that are 
distributed over 13.5 kb of genomic DNA. Exons are 
the regions of the gene sequence that code for the 
amino acids that constitute the glycoproteins, GPC 
and GPD. The introns separate the exons, and they 
are not encoded. Locations of the ATG (start codon) 
for initiation of GPC and GPD are indicated.














































































































GPC = glycophorin C; GPD = glycophorin D.
ˆ the altered GPC does not express Ana.
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Table 3. Differentiation of Ge-negative phenotypes using monoclonal 
anti-Ge4
RBCs Normal Yus Gerbich Leach
Untreated 4+ 0–2+ 0–2+ 0
Trypsin-treated 0 0 4+ 0
loss of the N-glycan and the gain of an O-glycan.24 Lsa (Ge6)
(Lewis)25 results from a novel amino sequence encoded by 
a duplication or triplication of exon 3 of GYPC. The allele 
with a duplication of exon 3 is the reciprocal product of the 
altered GYPC (GYPC.Ge) that lacks exon 3 and encodes the 
Gerbich phenotype.
Altered Antigen Expression
 In protein 4.1R–deficient RBCs, Gerbich antigens are 
expressed weakly. As GPC and GPD interact with protein 
4.1R, an absence of this protein causes a reduced level of 
GPC and GPD in the RBC membrane.12 The weakening of 
Ge2 and Ge3 antigens can be such that, under certain test-
ing conditions, they can appear to be absent.
 Gerbich-negative RBCs may show a weakened expres-
sion of certain other blood group antigens, notably Kell and 
Vel. Nine of 11 GE:–2,–3 samples showed different degrees 
of weakening of Kell system antigens, whereas none of six 
GE:–2,3 samples showed Kell depression.26 Similarly, 3 of 
14 examples of anti-Vel failed to react with four GE:–2,–3,4 
samples, but they did react with one example each of GE: 
–2,3,4 and GE:–2,–3,–4 RBC samples.27
Antibodies to Gerbich Antigens
Anti-Ge2
 Anti-Ge2 may be immune or naturally occurring and 
reacts with an antigen on GPD. Anti-Ge2 is usually an IgG 
antibody that reacts by the IAT. Some examples of anti-Ge2 
have been complement binding and hemolytic. Treatment 
of RBCs with papain or ficin results in the loss of reactivity 
with anti-Ge2; however, when RBCs treated with 200 mM 
DTT are tested with anti-Ge2, variable results are obtained. 
Individuals with Yus, Gerbich, or Leach phenotypes can 
make anti-Ge2 (Table 2).28 The clinical significance of anti-
Ge2 is discussed below.
Anti-Ge3
 Anti-Ge3 reacts with an antigen on both GPC and GPD. 
Anti-Ge3 is usually an IgG antibody that reacts by the IAT; 
however, some IgM forms have been reported. Many ex-
amples of anti-Ge3 bind complement and are hemolytic. 
Anti-Ge3 reacts with RBCs that were treated with papain or 
ficin and 200 mM DTT. Individuals with Gerbich or Leach 
phenotypes can make anti-Ge3 (Table 2).28 The clinical sig-
nificance of anti-Ge3 is discussed later.
Anti-Ge4
 Alloanti-Ge4 is very rare; only one human example has 
been described  That antibody was IgG, and it reacted by the 
IAT.29  Numerous examples of monoclonal antibodies with 
Ge4 specificity have been produced.30,31 Treatment of RBCs 
with papain or ficin results in the loss of reactivity with anti-
Ge4, however, treatment of RBCs with 200 mM DTT does 
not affect their reactivity with anti-Ge4.28 Individuals with 
Leach phenotype can make anti-Ge4 (Table 2).28 There is no 
information about the clinical significance of anti-Ge4.
Gerbich Antigens
 There are six high-prevalence antigens and five low-
prevalence antigens in the Gerbich blood group system. As 
examples of anti-Ge1 are no longer available, the Ge1 anti-
gen was declared to be obsolete by the ISBT working party 
for terminology of red cell surface antigens.
High-Prevalence Antigens
 Ge2 is absent from RBCs with the Yus, Gerbich, or 
Leach phenotype. Ge2 is located at the NH2 terminal 19 
amino acids of GPD and is not expressed on GPC. Ge3 is 
absent from RBCs with the Gerbich or Leach phenotype. 
Ge3 is expressed on both GPC and GPD within their extra-
cellular portion close to the lipid bilayer. Ge4 is absent only 
from RBCs with the Leach phenotype, which is the null phe-
notype in the Gerbich blood group system. Ge4 is located 
within the NH2 terminal 19 amino acids of GPC (Figure 1; 
Table 2).
 The Ge-negative phenotypes, which can be difficult 
to differentiate by hemagglutination with polyclonal anti-
bodies, are readily distinguished by testing trypsin-treated 
RBCs with monoclonal anti-Ge4. The reaction patterns are 
shown in Table 3.
 Three other high-prevalence Ge antigens, GEPL 
(Ge10*), GEAT (Ge11*), and GETI (Ge12*), are each a con-
sequence of a nucleotide change in GYPC (Table 1).19
Low-Prevalence Antigens
 Wb (Ge5)(Webb),21 Ana (Ge7)(Ahonen),11 Dha (Ge8)
(Duch),22 and GEIS (Ge9)23 each result from a nucleotide 
change in GYPC (Table 1). The Wb (Ge5) antigen results 
from the substitution Asn8Ser near the NH2 terminus of 
GPC. This substitution interrupts the consensus sequence 
for N-glycosylation (Asn-X-Ser/Thr), which results in a 
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Gerbich blood group system
Antibodies to Low-Prevalence Antigens
Wb(Ge5), Lsa(Ge6), Ana(Ge7), Dha(Ge8), GEIS (Ge9)
 These antibodies may be IgM or IgG, and they may be 
naturally occurring. They react at room temperature and 
by the IAT, and none are complement-binding. Treatment 
of antigen-positive RBCs with papain or ficin results in the 
loss of reactivity with these antibodies; however, the anti-
gens are resistant to treatment with 200 mM DTT.28 There 
are no reports of clinically significant transfusion reactions 
or HDFN associated with these antibodies.
Clinical Significance
Transfusion Reactions
 Some examples of anti-Ge2 and anti-Ge3 have caused 
moderate transfusion reactions—both immediate and de-
layed; however, other examples have failed to produce 
shortened RBC survival when antigen-positive incompat-
ible units were transfused.32–34 Pearson et al.35 reported a 
case of alloanti-Ge in which there were discrepant results 
between an in vivo chromium-51 (51Cr) survival study and 
an in vitro monocyte assay. In that case, the in vivo 51Cr sur-
vival study yielded zero survival of Gerbich-positive cells 
after 24 hours; however, a monocyte assay showed less 
than 1 percent lysis of Gerbich-positive cells. The clinical 
significance in this case was not determined because only 
Gerbich-negative blood was transfused during surgery.
HDFN
 Anti-Ge2 has been associated with a positive DAT in in-
fants with GE:2 RBCs; however, no cases of clinical HDFN 
have been reported. By contrast, anti-Ge3 appears to be ca-
pable of causing severe HDFN. An interesting recent publi-
cation shows that the mechanism for anemia, and possibly 
for thrombocytopenia, in HDFN caused by anti-Ge3 may 
be attributed to interference with the erythropoietin signal-
ing cascade.36 Similar to the mechanism of erythroid sup-
pression described in HDFN caused by anti-K,37 anti-Ge3 
has been associated with antibody-dependent hemolysis, as 
well as inhibition of erythroid progenitor cell growth in the 
infant. In these cases, the affected infants may require ini-
tial treatment at delivery, followed by monitoring for signs 
of anemia for several weeks after birth.38,39
Autoimmune Hemolytic Anemia
 Several cases of autoimmune hemolytic anemia (AIHA) 
with anti-Ge specificity have been reported. In two cases, 
the course of the AIHA was as expected, i.e., the patients 
typed Ge+, their serum demonstrated anti-Ge antibodies, 
their DATs were positive, and eluates from the autologous 
RBCs demonstrated Ge-like antibodies.40,41
 In one case, the patient typed Ge+ and the serum was 
nonreactive, but an eluate from the patient’s RBCs demon-
strated anti-Ge specificity.42 This is the first report of IgM-
mediated warm AIHA associated with autoanti-Ge. In two 
other cases, the patients typed Ge+ and their serum dem-
onstrated anti-Ge, but their serum failed to react with the 
autologous RBCs (DAT-negative).43,44 However, in both of 
these cases, eluates from the patients’ RBCs demonstrated 
an antibody with Ge specificity. Without the eluate results, 
these cases could have been confused with alloanti-Ge. One 
possible explanation for these findings could be a weakening 
of the Gerbich antigens during the course of the AIHA. In 
cases of severe life-threatening hemolysis, it might be ad-
visable to select Ge-negative units for transfusion.
Hereditary Elliptocytosis
 Gerbich antigens interact with protein 4.1R, which con-
tributes to the stability of the RBC membrane.12,45,46 In 1986, 
Daniels et al.31 described a family with hereditary elliptocy-
tosis that was associated with the Leach phenotype. In 1991, 
Telen et al.47 further explained the molecular basis for the 
elliptocytosis as the deficiency of GPC and GPD that is asso-
ciated with the Leach phenotype. Patients with hereditary 
elliptocytosis rarely require transfusions. If such a patient 
requires transfusions for other reasons (e.g., surgery) and 
the patient demonstrates alloanti-Ge, it might be prudent 
to select Gerbich-negative units for transfusion, if such rare 
blood is available.
Malaria
 In northern Papua New Guinea, where malaria is en-
demic, Serjeantson48 reported in 1989 that Gerbich-
negative Melanesians appear to have a selective advantage 
for avoiding infections with Plasmodium falciparum and 
Plasmodium vivax. Subsequent studies confirmed that P. 
falciparum binds to RBCs through a receptor on wild-type 
GPC, which is missing on Gerbich-negative cells that ex-
press a truncated form of GPC.49–51
Summary
 The Gerbich blood group system is composed of six 
high-prevalence antigens, which are expressed on GPC, 
GPD, or both. GPC and GPD are encoded by a single gene, 
GYPC, which is located on the long arm of chromosome 2. 
By interacting with protein 4.1R, GPC and GPD contribute 
stability to the RBC membrane, and a deficiency in these 
proteins has been associated with hereditary elliptocytosis. 
Also, Gerbich antigens apparently act as receptors for P. 
falciparum malaria. Certain Gerbich antibodies are clini-
cally significant, e.g., anti-Ge2 and anti-Ge3 have caused 
hemolytic transfusion reactions, and anti-Ge3 has produced 
HDFN.
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